Toward an effective gene therapy in renal disease
Since the first reports of the generation of transgenic of extracellular matrix synthesis. Evidence that TGF-␤ mice in 1980 [1] , technology aimed at manipulating the might contribute to fibrotic renal disease include: (1) the mammalian genome has yielded fruitful information redemonstration of enhanced expression of TGF-␤ peptide garding the potential physiological roles of gene products and/or mRNA in human renal fibrotic diseases and aniin vivo. From these technologies spawned the field of mal models of renal diseases [3]; (2) the demonstration gene therapy, the goal of which is to treat human diseases that increased TGF-␤ activity in vivo, by gene transfer through the introduction of foreign genetic material. The or transgenic methods, results in glomerular extracellular development of such technology may offer the best hope matrix accumulation, proteinuria, tubulointerstitial fiin the future treatment of monogenic diseases such as brosis and the onset of chronic renal failure [4] [5] [6] ; (3) cystic fibrosis where current treatments do not address the demonstration that proteinuria and extracellular mathe underlying cause. Gene therapy need not solely exist trix (ECM) accumulation associated with anti Thy-1.1 for the treatment of such genetic disorders, but may find nephritis was attenuated by a neutralizing antibody to widespread utility in treating acquired diseases in which TGF-␤ or the TGF-␤ antagonist, decorin [7, 8] . Thus, a protein is under-or over-expressed.
strategies that intervene with TGF-␤ extracellularly may Despite the ever-increasing knowledge of the genetic be of therapeutic utility. nature of diseases (that is, the identification of "culprit"
In this issue of Kidney International, Isaka et al report genes which lack proper function or proper expression), a novel and exciting twist on gene therapy strategies several practical considerations have kept gene therapy designed to reduce TGF-␤ hyperactivity in a rat model a "future prospect." These considerations include: (1) of glomerulonephritis [9] . TGF-␤'s biological effects are the method of introduction of foreign genetic material; manifested through signal-transducing receptors on the (2) the ability to target the expression of genetic material cell surface which are referred to as TGF-␤ receptors to relevant cell types; (3) the demonstration of practicaltype I and II, (T␤RI and T␤RII). While both receptor ity in animal models of diseases; (4) the ability to utilize subtypes possess serine kinase domains, active TGF-␤ this technology in patients without severe side-effects.
has strong affinity for the extracellular domain of T␤RII The reader is referred to the excellent article by Lipkoand only interacts with T␤RI after association with witz et al [2] that outlines several advances in these first T␤RII on the cell surface. It has been shown that a two considerations. Several options such as the adenovisoluble recombinant peptide containing the ligand bindrus, adeno-associated virus, retroviruses or the direct ing domain of T␤RII competitively inhibits TGF-␤ activinjection of DNA using lipofection reagents, continue ity in vitro [10] . to be refined as a means to introduce foreign DNA into
The report by Isaka et al [9] takes advantage of this mammalian cells. Furthermore, tissue and cell specificity, observation. The authors have designed a chimeric gene at least in kidney, appear likely to be achieved via a product containing the ligand binding domain of the combination of cell-specific promoters in combination T␤RII molecule with the Fc region of the IgG heavy with the proper vector and physical route of administrachain that contains intermolecular cysteine disulfide tion [2] . Experiments geared toward demonstrating the bonds. The resulting stabilized chimeric dimer is a potent practicality of a genetic approach toward therapy in anicompetitive inhibitor of TGF-␤ in vitro. Following transmal models of renal disease would appear to be the next fection into muscle in vivo, the expressed protein is remajor step.
leased extracellularly and is detected in kidney glomerThe problem of target specificity appears less imporuli. Its efficacy was determined by administration of the tant when humoral factors are involved. Evidence has chimeric construct one day after treatment with antiaccumulated suggesting a key role for transforming Thy 1.1 serum to rats. These animals manifested signifigrowth factor-beta (TGF-␤) as a possible mediator of cantly less glomerular matrix expansion than mock-vecseveral renal fibrotic diseases of both glomerular and tor treated controls. This same group of investigators tubular origin. In vitro, TGF-␤ is a potent stimulator has published similar findings following the in vivo transfection of the natural occurring TGF-␤ inhibitor, decorin [11] . Therefore, this report strengthens the argument 
